JNJ vs SNY vs KO vs PFE vs MRK

For growth investors, Sanofi (SNY) is the stronger pick with 5.

5% revenue growth year-over-year, versus -1. 6% for Pfizer Inc. (PFE). Merck & Co. , Inc. (MRK) offers the better valuation at 15. 6x trailing P/E (22. 2x forward), making it the more compelling value choice. Analysts rate Johnson & Johnson (JNJ) a "Buy" — based on 40 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Merck & Co.

, Inc. (MRK) is the cheapest at 15. 6x versus Johnson & Johnson at 39. 4x. On forward P/E, Pfizer Inc. is actually cheaper at 8. 5x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Merck & Co. , Inc. wins at 1. 04x versus Johnson & Johnson's 35. 11x — a reasonable growth-adjusted valuation.

Over the past 5 years, Merck & Co.

, Inc. (MRK) delivered a total return of +68. 5%, compared to -13. 7% for Pfizer Inc. (PFE). Over 10 years, the gap is even starker: MRK returned +160. 5% versus PFE's +23. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

23β versus Sanofi's 0. 43β — meaning SNY is approximately -283% more volatile than KO relative to the S&P 500. On balance sheet safety, Sanofi (SNY) carries a lower debt/equity ratio of 30% versus 133% for The Coca-Cola Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Sanofi (SNY) is pulling ahead at 5.

5% versus -1. 6% for Pfizer Inc. (PFE). On earnings-per-share growth, the picture is similar: The Coca-Cola Company grew EPS 23. 6% year-over-year, compared to -57. 8% for Johnson & Johnson. Over a 3-year CAGR, SNY leads at 4. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Merck & Co.

, Inc. (MRK) is the more profitable company, earning 28. 1% net margin versus 12. 4% for Pfizer Inc. — meaning it keeps 28. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MRK leads at 36. 2% versus 13. 6% for SNY. At the gross margin level — before operating expenses — SNY leads at 72. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Merck & Co. , Inc. (MRK) is the more undervalued stock at a PEG of 1. 04x versus Johnson & Johnson's 35. 11x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Pfizer Inc. (PFE) trades at 8. 5x forward P/E versus 24. 3x for The Coca-Cola Company — 15. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SNY: 20. 3% to $51. 00.

All stocks in this comparison pay dividends.

Pfizer Inc. (PFE) offers the highest yield at 6. 8%, versus 2. 1% for Johnson & Johnson (JNJ).

For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

23), 2. 6% yield, +115. 0% 10Y return). Both have compounded well over 10 years (KO: +115. 0%, SNY: +58. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (JNJ (Healthcare) and SNY (Healthcare) and KO (Consumer Defensive) and PFE (Healthcare) and MRK (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: JNJ is a large-cap quality compounder stock; SNY is a mid-cap income-oriented stock; KO is a large-cap quality compounder stock; PFE is a mid-cap income-oriented stock; MRK is a large-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.